PHILADELPHIA – After a kidney transplant, women may experience decreased kidney damage from ischemia reperfusion injury compared to men due to the impact of gender-specific hormones, suggests a new preclinical study and an analysis of patient data published online in the Journal of Clinical Investigation from researchers at the Perelman School of Medicine at the University of Pennsylvania.
The stopping and starting of blood flow to an organ can cause tissue damage called ischemia reperfusion injury (IRI), which is a common cause of kidney injury. Specifically in kidney transplantation, this damage can be severe enough to cause a condition known as delayed graft function (DGF), in which the transplanted kidney does not function immediately following transplantation, causing the patient to remain on dialysis as the organ recovers. However, animal data has suggested that females may be better protected from renal IRI.
To study these effects, researchers transplanted kidneys from male-to-male, male-to-female, female-to-female, and female-to-male mice and assessed whether the change in hormonal environment changed the tolerance of an IRI event. They found that females experienced less renal IRI, even with a kidney from a male donor. The renal function was assessed by blood urea nitrogen (BUN), a blood test used to measure kidney function, and later the kidneys were examined for the formation of fibrosis – evidence of long-lasting damage. Importantly, females treated with estrogen had even better tolerance of IRI than untreated female mice.
“What’s interesting is that when a male kidney was transplanted into a female recipient, the organ eventually reacted based on the recipient’s gender, and the reverse was also true,” said Matthew Levine, MD, PhD, an assistant professor of Transplant Surgery and principal investigator of the study. “This indicates that the kidney’s ischemia tolerance reflects its hormonal environment and indicates that hormonal treatment can have a positive effect. Males did not respond to estrogen treatment favorably, likely due to the negative impact of testosterone, but neutered male mice – with a lack of testosterone – did see beneficial effects with estrogen treatment.”
Levine and his team also analyzed the effects of gender on human transplantation using data collected by the United Organ Sharing Network (UNOS). Evaluating kidney recipients from 1997 to 2011, researchers examined delayed draft function within the first week after transplantation in both male and female patients. The occurrence of IRI in these patients supported the earlier finding that female recipients experienced less delayed graft function, and that this effect was not explained by differences in the body size of the recipients.
“The findings from the mouse models illustrating that estrogen leads to a lower occurrence of ischemia reperfusion injury was supported by national human kidney transplant data comprised of nearly 47,000 transplant recipients,” said David Aufhauser, MD, a fourth-year general surgery resident, research fellow, and a co-author of the study. “As this is the first study to our knowledge to evaluate gender effects on IRI in kidney transplantation, this data justifies further investigation into using hormones to improve kidney function after ischemia.”
The data show that gender significantly affects renal IRI tolerance in mice and humans.
“While our primary interest is in transplantation, there is potential for these findings to impact the treatment of patients in other areas, such as heart and vascular surgery and trauma,” said Levine. “While more research is definitely needed, these initial results imply a potential for therapeutic intervention with estrogen to improve ischemia tolerance, at least in female patients.”
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.